{"id":2663,"date":"2019-02-28T17:12:40","date_gmt":"2019-02-28T17:12:40","guid":{"rendered":"https:\/\/www.sfj-pharma.com\/?p=848"},"modified":"2021-02-10T18:34:22","modified_gmt":"2021-02-10T18:34:22","slug":"apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/","title":{"rendered":"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae"},"content":{"rendered":"\n<p><strong>Apellis\nPharmaceuticals Announces Collaboration with SFJ Pharmaceuticals<\/strong>\u00ae<strong> for APL-2 in\nHematologic Indications<\/strong><strong><\/strong><\/p>\n\n\n\n<p class=\"has-text-align-center\"><em>Apellis to receive up to $120 million in upfront and near-term\nmilestone payments, with the potential for additional payments subject to mutual\nagreement <\/em><\/p>\n\n\n\n<p class=\"has-text-align-center\"><em>Apellis retains exclusive worldwide commercial rights to APL-2 in\nall indications<\/em><\/p>\n\n\n\n<p>WALTHAM Mass., and CRESTWOOD, Ky., February 28, 2019 (GLOBE\nNEWSWIRE) \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yHuI51xuaIfx-x3w23uAP77g3SHd8cEGzFDZDs2Ukw74LtD9xeHccsPvZ6vj9_JF92Rqfhm6PT0QGsNVx8YXQansfEd4g9KOvlaYXu-H55A=\" target=\"_blank\" rel=\"noreferrer noopener\">Apellis Pharmaceuticals<\/a>&nbsp;Inc.,\n(Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the\ndevelopment of novel therapeutic compounds to treat disease through the\ninhibition of the complement system, today announced a novel, risk-sharing\ncollaboration to support the development of APL-2 in hematologic indications\nwith SFJ Pharmaceuticals, a global drug development company backed by\nBlackstone Life Sciences and Abingworth. <\/p>\n\n\n\n<p>This collaboration marks the first time that SFJ Pharmaceuticals has partnered with a pre-revenue biopharma company. As part of this collaboration, SFJ and Apellis have entered into an agreement to support the development of APL-2 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Under the terms of the agreement, SFJ has agreed to pay Apellis $60 million in support of the PNH clinical program following deal close, with up to an additional $60 million based on Apellis meeting specific, pre-defined clinical milestones that are expected in 2019 and associated with the PNH development program, and subject to Apellis meeting certain capital requirements. Subject to mutual agreement, SFJ may also pay Apellis an additional $50 million in funding for the PNH clinical program following a specified, pre-defined clinical milestone.<\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong><a href=\"https:\/\/www.sfj-pharma.com\/wp-content\/uploads\/2019\/02\/APLS-SFJ-PR-2.28.19.pdf\">Read Full Press Release<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae for APL-2 in Hematologic Indications Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide commercial rights to APL-2 in all&#8230;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[103],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae - SFJ Pharmaceuticals<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae - SFJ Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae for APL-2 in Hematologic Indications Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide commercial rights to APL-2 in all...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"SFJ Pharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-28T17:12:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-02-10T18:34:22+00:00\" \/>\n<meta name=\"author\" content=\"khateam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"khateam\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/\"},\"author\":{\"name\":\"khateam\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc\"},\"headline\":\"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae\",\"datePublished\":\"2019-02-28T17:12:40+00:00\",\"dateModified\":\"2021-02-10T18:34:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/\"},\"wordCount\":248,\"publisher\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/\",\"url\":\"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/\",\"name\":\"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae - SFJ Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#website\"},\"datePublished\":\"2019-02-28T17:12:40+00:00\",\"dateModified\":\"2021-02-10T18:34:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sfj-pharma.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#website\",\"url\":\"https:\/\/www.sfj-pharma.com\/\",\"name\":\"SFJ Pharmaceuticals\",\"description\":\"Resources for Accelerated Clinical Development\",\"publisher\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sfj-pharma.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\",\"name\":\"SFJ Pharmaceuticals\",\"url\":\"https:\/\/www.sfj-pharma.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552\",\"contentUrl\":\"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552\",\"width\":750,\"height\":205,\"caption\":\"SFJ Pharmaceuticals\"},\"image\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc\",\"name\":\"khateam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g\",\"caption\":\"khateam\"},\"sameAs\":[\"https:\/\/www.sfj-pharma.com\"],\"url\":\"https:\/\/www.sfj-pharma.com\/author\/khateam\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae - SFJ Pharmaceuticals","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae - SFJ Pharmaceuticals","og_description":"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae for APL-2 in Hematologic Indications Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide commercial rights to APL-2 in all...","og_url":"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/","og_site_name":"SFJ Pharmaceuticals","article_published_time":"2019-02-28T17:12:40+00:00","article_modified_time":"2021-02-10T18:34:22+00:00","author":"khateam","twitter_card":"summary_large_image","twitter_misc":{"Written by":"khateam","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/"},"author":{"name":"khateam","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc"},"headline":"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae","datePublished":"2019-02-28T17:12:40+00:00","dateModified":"2021-02-10T18:34:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/"},"wordCount":248,"publisher":{"@id":"https:\/\/www.sfj-pharma.com\/#organization"},"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/","url":"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/","name":"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae - SFJ Pharmaceuticals","isPartOf":{"@id":"https:\/\/www.sfj-pharma.com\/#website"},"datePublished":"2019-02-28T17:12:40+00:00","dateModified":"2021-02-10T18:34:22+00:00","breadcrumb":{"@id":"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sfj-pharma.com\/apellis-pharmaceuticals-announces-collaboration-with-sfj-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sfj-pharma.com\/"},{"@type":"ListItem","position":2,"name":"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.sfj-pharma.com\/#website","url":"https:\/\/www.sfj-pharma.com\/","name":"SFJ Pharmaceuticals","description":"Resources for Accelerated Clinical Development","publisher":{"@id":"https:\/\/www.sfj-pharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sfj-pharma.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.sfj-pharma.com\/#organization","name":"SFJ Pharmaceuticals","url":"https:\/\/www.sfj-pharma.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552","contentUrl":"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552","width":750,"height":205,"caption":"SFJ Pharmaceuticals"},"image":{"@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc","name":"khateam","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g","caption":"khateam"},"sameAs":["https:\/\/www.sfj-pharma.com"],"url":"https:\/\/www.sfj-pharma.com\/author\/khateam\/"}]}},"rttpg_featured_image_url":null,"rttpg_author":{"display_name":"khateam","author_link":"https:\/\/www.sfj-pharma.com\/author\/khateam\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.sfj-pharma.com\/category\/news\/\" rel=\"category tag\">News<\/a>","rttpg_excerpt":"Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals\u00ae for APL-2 in Hematologic Indications Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide commercial rights to APL-2 in all...","_links":{"self":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/2663"}],"collection":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/comments?post=2663"}],"version-history":[{"count":1,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/2663\/revisions"}],"predecessor-version":[{"id":7058,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/2663\/revisions\/7058"}],"wp:attachment":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/media?parent=2663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/categories?post=2663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/tags?post=2663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}